453 related articles for article (PubMed ID: 34726078)
1. Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat.
Mitsuboshi S; Niimura T; Kanda M; Ishida S; Zamami Y; Ishizawa K
Ann Pharmacother; 2022 Aug; 56(8):910-915. PubMed ID: 34726078
[TBL] [Abstract][Full Text] [Related]
2. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.
Ikemura K; Hiramatsu SI; Shinogi Y; Nakatani Y; Tawara I; Iwamoto T; Katayama N; Okuda M
Sci Rep; 2019 Dec; 9(1):20359. PubMed ID: 31889141
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.
Huang C; Xia F; Xue L; Liu L; Bian Y; Jin Z; Miao L
Cancer Chemother Pharmacol; 2020 Feb; 85(2):433-441. PubMed ID: 31691080
[TBL] [Abstract][Full Text] [Related]
5. Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP).
Markowicz-Piasecka M; Huttunen J; Montaser A; Adla SK; Auriola S; Lehtonen M; Huttunen KM
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299347
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
[TBL] [Abstract][Full Text] [Related]
7. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
Ju C; Lai RWC; Li KHC; Hung JKF; Lai JCL; Ho J; Liu Y; Tsoi MF; Liu T; Cheung BMY; Wong ICK; Tam LS; Tse G
Rheumatology (Oxford); 2020 Sep; 59(9):2340-2349. PubMed ID: 31873735
[TBL] [Abstract][Full Text] [Related]
8. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
[TBL] [Abstract][Full Text] [Related]
9. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Lertnawapan R; Jatuworapruk K
Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
[TBL] [Abstract][Full Text] [Related]
11. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Spina M; Nagy Z; Ribera JM; Federico M; Aurer I; Jordan K; Borsaru G; Pristupa AS; Bosi A; Grosicki S; Glushko NL; Ristic D; Jakucs J; Montesinos P; Mayer J; Rego EM; Baldini S; Scartoni S; Capriati A; Maggi CA; Simonelli C;
Ann Oncol; 2015 Oct; 26(10):2155-61. PubMed ID: 26216382
[TBL] [Abstract][Full Text] [Related]
12. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
Rhee MS; Schneider E
Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
Volk EL; Farley KM; Wu Y; Li F; Robey RW; Schneider E
Cancer Res; 2002 Sep; 62(17):5035-40. PubMed ID: 12208758
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
[TBL] [Abstract][Full Text] [Related]
16. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
[TBL] [Abstract][Full Text] [Related]
17. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.
Bardin T; Chalès G; Pascart T; Flipo RM; Korng Ea H; Roujeau JC; Delayen A; Clerson P
Joint Bone Spine; 2016 May; 83(3):314-7. PubMed ID: 26709250
[TBL] [Abstract][Full Text] [Related]
18. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
[TBL] [Abstract][Full Text] [Related]
19. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
20. Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study.
Rey A; Batteux B; Laville SM; Marienne J; Masmoudi K; Gras-Champel V; Liabeuf S
Arthritis Res Ther; 2019 Nov; 21(1):229. PubMed ID: 31703711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
